Hypopharyngeal carcinomas most frequently harbor alterations in TP53, CDKN2A, and CCND1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and CCND1 Amplification are the most common alterations in hypopharyngeal carcinoma .
There are 3 clinical trials for hypopharyngeal carcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain hypopharyngeal carcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).
ERBB2 is the most frequent gene inclusion criterion for hypopharyngeal carcinoma clinical trials .
Demplatin pegraglumer, enfortumab vedotin, and lenalidomide are the most common interventions in hypopharyngeal carcinoma clinical trials.
Significant Genes in Hypopharyngeal Carcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.